Health Affairs This Week11 Kesä 2021

Insights into FDA's controversial decision to approve a new Alzheimer's treatment drug

This week, the US Food and Drug Administration approved Aduhelm (aducanumab) to treat patients with Alzheimer's disease using an accelerated approval pathway.

The drug was approved on June 7, 2021, and the decision was quick to spark controversy. At least two members of a panel of outside advisors to the FDA from Mayo Clinic and Washington University resigned in protest over the drug's approval.

Clinical trials for the drug, which is manufactured by Biogen, showed a reduction in amyloid beta plaques. According to the FDA, that is "a hallmark finding in the brain of patients with Alzheimer's" and "is expected to lead to a reduction in the clinical decline of this...form of dementia."

But there remain concerns about the drug's side effects in addition to its price tag.

Health Affairs' Senior Editor Leslie Erdelack joins Deputy Editor for Special Content Rob Lott on this episode of Health Affairs This Week to discuss the approval and review outstanding questions, drug pricing, and whether pharmaceutical companies might look to old data for new drug approvals.

Related Links:

The FDA's Approval of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues and Stakeholders (Health Affairs Blog)
Limiting Coverage Based On Efficacy And Safety: A Path For Medicare Regarding The Alzheimer's Treatment Aducanumab (Health Affairs Blog)
The Search For Effective Alzheimer's Therapies: A Work In Progress (Health Affairs)

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(279)

Medicare Advantage's $16 Billion Quality Bonus Program: Litigation, Reform, and Rising Costs

Health Affairs Publishing's Jeff Byers welcomes Erica Socker of Georgetown University to the pod to discuss her recent Forefront article that explores how the Medicare Advantage quality bonus program ...

21 Elo 18min

AI and the Future of Patient Empowerment

In this episode of Health Affairs This Week, David Betts, founder and board chair at StoryFlight Labs, shares how his ALS diagnosis inspired him to launch StoryFlight Labs and develop Talk To Me Goose...

14 Elo 20min

When Academic Research Meets The Attention Economy

On this episode, Health Affairs Publishing's Jeff Byers gets meta and invites Kent Anderson and Joy Moore, authors of the new book How The Internet Disrupted Science, onto the podcast to discuss how m...

7 Elo 14min

BEST OF: Future of Primary Care: Bright or Broken? w/ Troyen Brennan

Health Affairs This Week is on vacation in July. We will return with new episodes in August 2026.This episode originally aired on October 25, 2025.Health Affairs This Week will return with new episode...

29 Heinä 19min

Health Research Funding Suddenly Cut: Dr. Aaron Carroll Explains

We interrupt the summer break for this special "emergency pod" episode. Health Affairs Publishing's Jeff Byers welcomes Dr. Aaron Carroll, President and CEO of AcademyHealth, back to the pod to examin...

23 Heinä 17min

BEST OF: The Great Health Care Vision Board (Stacie Dusetzina)

Health Affairs This Week is on vacation in July. We will return with new episodes in August 2026. This episode originally aired on January 21, 2026.On an emergency pod episode, Health Affairs' Jeff By...

22 Heinä 20min

BEST OF: CMS's 10-Year Value-Based Primary Care Experiment

Health Affairs This Week is on vacation in July. We will return with new episodes in August 2026. This episode originally aired on June 23, 2023. Health Affairs' Marianne Amoss and Michael Gerber brea...

15 Heinä 14min

BEST OF: Is Value-Based Payment Failing U.S. Healthcare? | Andrew Ryan

This episode originally aired on February 27, 2026.Health Affairs’ Jeff Byers welcomes Brown University's Andrew Ryan to the pod to discuss his recent Forefront article that explores whether value-bas...

8 Heinä 19min